-
Mast Cell–Mesothelial Crosstalk in Peritoneal Fibrosis
2026-08-23
A 2026 study identifies tryptase/PAR2-mediated communication between mast cells and peritoneal mesothelial cells as a mechanistic driver of peritoneal fibrosis. By combining chemical profiling, computational target analysis, mouse modeling, transcriptomics, and cell-based validation, the authors show that Astragalus membranaceus and Salvia miltiorrhiza suppress this inflammatory-fibrotic axis.
-
Aclacinomycin A and Persistent rDNA Stress
2026-08-22
Aclacinomycin A (Aclarubicin) is a versatile DNA damage inducer for connecting topoisomerase stress with apoptosis and nucleolar genome surveillance. This article presents an assay-centered framework for interpreting rDNA damage, PML responses, caspase activation, and proteasome-related confounding effects.
-
Rosiglitazone: A Functional Lens on PPARγ Disease
2026-08-22
Rosiglitazone, also known as Brl-49653, is widely used to study PPARγ biology and insulin sensitivity. This article develops a genotype-aware framework based on PPARG R212W research, showing how receptor stability, mitochondrial function, and pharmacologic rescue should shape experimental design.
-
EdU Imaging Kits (HF594) for PNI Assays
2026-08-21
EdU Imaging Kits (HF594) connect S-phase DNA synthesis measurement with microscopy and flow cytometry in pancreatic cancer–Schwann cell models. Their antibody-free click-chemistry workflow is especially useful for testing how PGE2-driven Schwann cell remodeling influences tumor–nerve interactions without harsh DNA denaturation.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-08-20
The reference study develops a localized tumor-suppressor replacement strategy in which chemically modified p21 mRNA is encapsulated in lipid nanoparticles and administered intravesically. Across expression analyses, cellular experiments, biodistribution studies, and an orthotopic mouse model, p21-LNP restored nuclear p21 activity and suppressed bladder tumor growth with limited systemic exposure.
-
Panobinostat (LBH589) Experimental Workflows
2026-08-20
Panobinostat (LBH589) combines broad HDAC inhibition with measurable chromatin, transcriptional, and apoptotic outputs. This guide translates its activity into practical workflows for multiple myeloma research, drug-resistance models, and mechanism-focused cell-death assays.
-
Neticonazole Hydrochloride: From Skin to Colon
2026-08-19
Neticonazole Hydrochloride is an imidazole antifungal with applications spanning cutaneous mycoses and exploratory colorectal cancer research. This article provides an evidence-aware framework for separating fungal membrane assays, exosome studies, apoptosis readouts, and colon-targeted delivery decisions.
-
VX-702: Practical p38α MAPK Assay Workflows
2026-08-19
VX-702 combines potent, selective p38α MAPK inhibition with a workflow-friendly profile for cytokine, platelet, arthritis, and ischemia-reperfusion studies. This guide translates kinase-mechanism findings into practical dosing, controls, readouts, and troubleshooting strategies without confusing biochemical potency with cellular response.
-
Cardiogreen (Indocyanine Green) Lab Guide
2026-08-18
A scenario-driven guide to using Cardiogreen (Indocyanine Green), SKU B8315, in cell viability, proliferation, cytotoxicity, and photodynamic workflows. It connects formulation, optical controls, protocol design, and interpretation with practical evidence and cited literature.
-
Dasatinib (BMS-354825) for Cancer Signaling
2026-08-18
Dasatinib (BMS-354825) provides a practical way to interrogate Src and Bcr-Abl signaling across phosphorylation, migration, EMT, and metastasis assays. This workflow connects validated prostate and PDAC model observations with hypothesis-driven studies of the SNAI1–PIK3R2/p-EphA2 axis in thymic epithelial tumors.
-
Tacrine hydrochloride hydrate in AD Assays
2026-08-17
Tacrine hydrochloride hydrate, also known as Tetrahydroaminacrine, connects quantitative cholinesterase inhibition with cell-based neuroprotection workflows. This guide shows how to use it as a mechanistic benchmark, troubleshoot assay artifacts, and evaluate tacrine-based designs without confusing cholinergic activity with general cytotoxicity.
-
EdU Imaging Kits (Cy5) in Pulmonary Hypertension
2026-08-17
A mechanistic and translational guide to using EdU-based S-phase measurements to connect hypoxia-driven endothelial proliferation with the HIF1α–PRDX1–DRP1 axis in pulmonary vascular remodeling.
-
Resveratrol Workflows for SIRT1 Neuroprotection
2026-08-16
Build a mechanism-resolved Resveratrol neuroprotection workflow around SIRT1, mitochondrial biogenesis, and apoptosis rather than relying on a single viability endpoint. This guide connects N2a-cell assay design with practical formulation, dose selection, controls, and troubleshooting for more reproducible translational studies.
-
Obeticholic Acid: A Mechanism-First Assay Strategy
2026-08-15
Obeticholic Acid is a selective FXR agonist for dissecting bile acid regulation, fibrotic signaling, and hepatic inflammation. This mechanism-first guide connects FXR assays with insights from 2025 11β-HSD1 fibrosis research to improve experimental decision-making.
-
Dimetridazole Workflows for Antimicrobial Research
2026-08-14
Dimetridazole supports more than endpoint growth inhibition: it can connect bacterial culture assay design with quorum sensing, biofilm, combination, infection model, and electrochemical workflows. This practical guide translates mechanistic and degradation evidence into controlled assay choices, quantitative starting conditions, and troubleshooting safeguards.